Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

New developments in the treatment of colorectal malignancies

Dr Richard Kim - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
New developments in the treatment of colorectal malignancies ( Dr Richard Kim - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )
8 Jul 2022

Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma

Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma ( Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain )
1 Jul 2022

Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer

Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey
Using combined oral contraceptives may decrease risk of Ovarian, Endometrial and Colorectal cancer ( Dr Mustafa Kamani - Hacettepe University Faculty of Medicine, Ankara, Turkey )
30 Jun 2022

Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial

Dr Maximilian Merz - Leipzig University, Leipzig, Germany
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )
28 Jun 2022

War in Ukraine: Global cancer aid to support refugees

Dr Horia Vulpe , Dr Ruslan Baltaga
War in Ukraine: Global cancer aid to support refugees ( Dr Horia Vulpe , Dr Ruslan Baltaga )
21 Jun 2022

War in Ukraine: The International Brain Tumour Alliance's response to aiding refugees during the crisis

Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance
War in Ukraine: The International Brain Tumour Alliance's response to aiding refugees during the crisis ( Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance )
21 Jun 2022

Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphoma shows a clinically meaningful PFS

Dr Carol Moreno - University of Barcelona, Barcelona, Spain
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphoma shows a clinically meaningful PFS ( Dr Carol Moreno - University of Barcelona, Barcelona, Spain )
21 Jun 2022

Rucaparib effective as maintenance therapy following first-line platinum-based chemo in ovarian cancer

Dr Bradley Monk - University of Arizona College, Tucson, USA
Rucaparib effective as maintenance therapy following first-line platinum-based chemo in ovarian cancer ( Dr Bradley Monk - University of Arizona College, Tucson, USA )
21 Jun 2022

RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malignancies

Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France
RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malignancies ( Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France )
17 Jun 2022

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022

A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma

Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands
A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )
13 Jun 2022

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )
13 Jun 2022